Incyte | Actif À Court Terme



Current Assets Changement Date
Acadia Pharmaceuticals USD 938.32M 150.03M 2024-12
Agios Pharmaceuticals USD 968.62M 3.02M 2025-03
Alnylam Pharmaceuticals USD 3.27B 27.03M 2025-03
Amgen USD 26.93B 2.1B 2025-03
Biogen USD 7.63B 169.2M 2025-03
BioMarin Pharmaceutical USD 3.47B 235.48M 2025-03
Bristol-Myers Squibb USD 30.78B 1B 2025-03
Eli Lilly USD 41.26B 8.52B 2025-03
Exelixis USD 1.47B 82.14M 2025-01
Gilead Sciences USD 19.17B 4.39B 2024-12
Incyte USD 3.23B 7.24M 2025-03
Ionis Pharmaceuticals USD 2.42B 201.36M 2025-03
MacroGenics USD 217.49M 4.71M 2024-12
Merck USD 35.5B 3.28B 2025-03
Moderna USD 6.77B 1.33B 2025-03
Neurocrine Biosciences USD 1.72B 151.9M 2024-12
Novartis USD 29.7B 1.56B 2024-12
Novartis USD 29.7B 1.56B 2024-12
Pfizer USD 45.86B 4.5B 2025-03
PTC Therapeutics USD 2.32B 950.88M 2025-03
Regeneron Pharmaceuticals USD 17.57B 9.64B 2025-03
Sarepta Therapeutics USD 2.43B 640.93M 2025-03
Ultragenyx Pharmaceutical USD 817.12M 17.52M 2024-12
Vertex Pharmaceuticals USD 9.6B 207.7M 2024-12



Incyte Actif À Court Terme - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - May 2025.